Carbon-11 Acetate and Fludeoxyglucose F 18 PET Scan of the Bone in Patients With Metastatic Prostate Cancer That Has Spread to the Bone

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Male

Summary

RATIONALE: Imaging procedures, such as PET scan, may help doctors predict a patient's response to treatment and help plan the best treatment.

PURPOSE: This clinical trial is studying carbon-11 acetate and fludeoxyglucose F 18 PET scan of the bone in patients with metastatic prostate cancer that has spread to the bone.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Washington
• Collaborator: National Cancer Institute (NCI)
• Treatments: Androgen Antagonists; Docetaxel; Fluorodeoxyglucose F18

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of prostate cancer, meeting 1 of the following criteria:

• Metastatic hormone-sensitive disease prior to initiation of first-line androgen-deprivation therapy and meets the following criteria:

• Histologic confirmation of original diagnosis

• Hormone-sensitive is defined as progressive disease in the absence of androgen-deprivation therapy

• Presence of ≥ 3 convincing bone metastases, as defined by bone scintigraphy, CT scan (MRI if indicated), or plain x-ray

• Metastatic hormone-refractory disease prior to initiation of a first-line chemotherapy regimen that includes docetaxel and meets the following criteria:

• Histologic confirmation of original diagnosis

• Hormone-refractory is defined as development or advancement of metastatic disease with castrate testosterone levels (total testosterone < 20 ng/dL)

• Presence of ≥ 3 convincing bone metastases, as defined by bone scintigraphy, CT scan (MRI if indicated), or plain x-ray

• Must have castrate testosterone levels (< 20 ng/dL) from orchiectomy or undergoing maintenance with a luteinizing hormone-releasing hormone agonist

• Outside the window of a potential antiandrogen withdrawal response (either decline in prostate-specific antigen or objective response by imaging)

PATIENT CHARACTERISTICS:

• Life expectancy > 12 weeks

• No serious underlying medical condition that would otherwise impair the patient's ability to receive treatment and undergo imaging studies

• No condition that would alter the patient's mental status, prohibiting the basic understanding and/or authorization of informed consent

• Able to lie still for the imaging

• Weight ≤ 300 lbs

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• At least 6 weeks since prior bicalutamide or nilutamide

• At least 4 weeks since prior flutamide, ketoconazole, diethylstilbestrol, or estradiol

• More than 4 weeks since prior bisphosphonate therapy

• More than 4 weeks since prior radiotherapy to the bone

• More than 4 weeks since prior radiopharmaceutical treatment to the bone

• No concurrent radiotherapy